The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes.
Local tissue concentrations of glucocorticoids are modulated by the enzyme 11beta-hydroxysteroid dehydrogenase which interconverts cortisol and the inactive glucocorticoid cortisone in man, and corticosterone and 11-dehydrocorticosterone in rodents. The type I isoform (11beta-HSD1) is a bidirectional enzyme but acts predominantly as a oxidoreductase to form the active glucocorticoids cortisol or corticosterone, while the type II enzyme (11beta-HSD2) acts unidirectionally producing inactive 11-keto metabolites. There are no known clinical conditions associated with 11beta-HSD1 deficiency, but gene deletion experiments in the mouse indicate that this enzyme is important both for the maintenance of normal serum glucocorticoid levels, and in the activation of key hepatic gluconeogenic enzymes. Other important sites of action include omental fat, the ovary, brain and vasculature. Congenital defects in the 11beta-HSD2 enzyme have been shown to account for the syndrome of apparent mineralocorticoid excess (AME), a low renin severe form of hypertension resulting from the overstimulation of the non-selective mineralocorticoid receptor by cortisol in the distal tubule of the kidney. Inactivation of the 11beta-HSD2 gene in mice results in a phenotype with similar features to AME. In addition, these mice show high neonatal mortality associated with marked colonic distention, and remarkable hypertrophy and hyperplasia of the distal tubule epithelia. 11Beta-HSD2 also plays an important role in decreasing the exposure of the fetus to the high levels of maternal glucocorticoids. Recent work suggests a role for 11beta-HSD2 in non-mineralocorticoid target tissues where it would modulate glucocorticoid access to the glucocorticoid receptor, in invasive breast cancer and as a mechanism providing ligand for the putative 11-dehydrocorticosterone receptor. While previous homologies between members of the SCAD superfamily have been of the order of 20-30% phylogenetic analysis of a new branch of retinol dehydrogenases indicates identities of > 60% and overlapping substrate specificities. The availability of crystal structures of family members has allowed the mapping of conserved 11beta-HSD domains A-D to a cleft in the protein structure (cofactor binding domain), two parallel beta-sheets, and an alpha-helix (active site), respectively.
Baker Medical Research Institute, Alfred Hospital, Melbourne, Australia. zygmunt.krozowski@baker.edu.au
Z
Z
Krozowski
K X
KX
Li
K
K
Koyama
R E
RE
Smith
V R
VR
Obeyesekere
A
A
Stein-Oakley
H
H
Sasano
C
C
Coulter
T
T
Cole
K E
KE
Sheppard
D042842:11-beta-Hydroxysteroid Dehydrogenases; D000818:Animals; D001160:Arterioles / Q000201:enzymology; D001921:Brain / Q000201:enzymology; D003345:Corticosterone / Q000031:analogs & derivatives / Q000378:metabolism; D006801:Humans; D006913:Hydroxysteroid Dehydrogenases / Q000737:chemistry / Q000378:metabolism*; D007527:Isoenzymes / Q000737:chemistry / Q000378:metabolism*; D007668:Kidney / Q000201:enzymology; D009369:Neoplasms / Q000201:enzymology; D010920:Placenta / Q000201:enzymology; D011487:Protein Conformation; D011965:Receptors, Glucocorticoid / Q000378:metabolism
D007527:Isoenzymes; D011965:Receptors, Glucocorticoid; D006913:Hydroxysteroid Dehydrogenases; D042842:11-beta-Hydroxysteroid Dehydrogenases; C003552:11-dehydrocorticosterone; D003345:Corticosterone